Under the 2023 collaboration agreement, Assembly Bio will receive $35 million for Gilead’s exercise of the HSV program option
Production at Biocon Biologics’ own facilities is scheduled to begin once technology transfers and regulatory approvals are finalized
GSK will make most of its inhaled respiratory portfolio and other products available on a direct purchasing platform, offering savings of up to 66%
The pharma company will donate more than seven tons of its active pharmaceutical ingredient (API) to bolster the American supply chain
The pharmaceutical giant now expects 2026 revenues to land between $59.5 billion and $62.5 billion
Clinical trial enrollment has long been a bottleneck in drug development
Updated results from the EMBER-3 study showed that the drug -- Inluriyo (imlunestrant) -- as a standalone treatment cut the risk of progression or death by 38%
The FDA aims to make a decision by April 8, 2026
The Phase 2 study tested two dose levels of pumitamig alongside four standard chemotherapy regimens across first
Subscribe To Our Newsletter & Stay Updated
